368 related articles for article (PubMed ID: 19144999)
1. Adequate phosphate binding with lanthanum carbonate attenuates arterial calcification in chronic renal failure rats.
Neven E; Dams G; Postnov A; Chen B; De Clerck N; De Broe ME; D'Haese PC; Persy V
Nephrol Dial Transplant; 2009 Jun; 24(6):1790-9. PubMed ID: 19144999
[TBL] [Abstract][Full Text] [Related]
2. Effects of Sucroferric Oxyhydroxide Compared to Lanthanum Carbonate and Sevelamer Carbonate on Phosphate Homeostasis and Vascular Calcifications in a Rat Model of Chronic Kidney Failure.
Phan O; Maillard M; Malluche HH; Stehle JC; Funk F; Burnier M
Biomed Res Int; 2015; 2015():515606. PubMed ID: 26221597
[TBL] [Abstract][Full Text] [Related]
3. [Experimental study of the mechanism for vascular calcification in chronic kidney disease].
Persy V
Verh K Acad Geneeskd Belg; 2008; 70(4):285-303. PubMed ID: 19166100
[TBL] [Abstract][Full Text] [Related]
4. Phosphate binders prevent phosphate-induced cellular senescence of vascular smooth muscle cells and vascular calcification in a modified, adenine-based uremic rat model.
Yamada S; Tatsumoto N; Tokumoto M; Noguchi H; Ooboshi H; Kitazono T; Tsuruya K
Calcif Tissue Int; 2015 Apr; 96(4):347-58. PubMed ID: 25511229
[TBL] [Abstract][Full Text] [Related]
5. Development and reversibility of impaired mineralization associated with lanthanum carbonate treatment in chronic renal failure rats.
Bervoets AR; Oste L; Behets GJ; Dams G; Blust R; Marynissen R; Geryl H; De Broe ME; D'Haese PC
Bone; 2006 Jun; 38(6):803-10. PubMed ID: 16412714
[TBL] [Abstract][Full Text] [Related]
6. High phosphate feeding induced arterial medial calcification in uremic rats: roles of Lanthanum carbonate on protecting vasculature.
Yu C; Chen B; Zhao T; Wang R; Akhtar J; Wang H; Zhang H
Life Sci; 2013 Oct; 93(17):646-53. PubMed ID: 24012609
[TBL] [Abstract][Full Text] [Related]
7. Phosphate binders in CKD: chalking out the differences.
Rees L; Shroff RC
Pediatr Nephrol; 2010 Mar; 25(3):385-94. PubMed ID: 19898877
[TBL] [Abstract][Full Text] [Related]
8. Does the phosphate binder lanthanum carbonate affect bone in rats with chronic renal failure?
Behets GJ; Dams G; Vercauteren SR; Damment SJ; Bouillon R; De Broe ME; D'Haese PC
J Am Soc Nephrol; 2004 Aug; 15(8):2219-28. PubMed ID: 15284308
[TBL] [Abstract][Full Text] [Related]
9. Effects of efficient phosphate binding on bone in chronic renal failure rats.
Behets GJ; Gritters M; Dams G; De Broe ME; D'Haese PC
Ren Fail; 2005; 27(4):475-84. PubMed ID: 16060138
[TBL] [Abstract][Full Text] [Related]
10. Chronic renal failure is associated with increased tissue deposition of lanthanum after 28-day oral administration.
Lacour B; Lucas A; Auchère D; Ruellan N; de Serre Patey NM; Drüeke TB
Kidney Int; 2005 Mar; 67(3):1062-9. PubMed ID: 15698446
[TBL] [Abstract][Full Text] [Related]
11. A comparative review of the efficacy and safety of established phosphate binders: calcium, sevelamer, and lanthanum carbonate.
Sprague SM
Curr Med Res Opin; 2007 Dec; 23(12):3167-75. PubMed ID: 17991307
[TBL] [Abstract][Full Text] [Related]
12. Lanthanum carbonate prevents accelerated medial calcification in uremic rats: role of osteoclast-like activity.
Che Y; Bing C; Akhtar J; Tingting Z; Kezhou Y; Rong W
J Transl Med; 2013 Dec; 11():308. PubMed ID: 24330832
[TBL] [Abstract][Full Text] [Related]
13. The antioxidant tempol ameliorates arterial medial calcification in uremic rats: important role of oxidative stress in the pathogenesis of vascular calcification in chronic kidney disease.
Yamada S; Taniguchi M; Tokumoto M; Toyonaga J; Fujisaki K; Suehiro T; Noguchi H; Iida M; Tsuruya K; Kitazono T
J Bone Miner Res; 2012 Feb; 27(2):474-85. PubMed ID: 21987400
[TBL] [Abstract][Full Text] [Related]
14. Lanthanum: a safe phosphate binder.
Persy VP; Behets GJ; Bervoets AR; De Broe ME; D'Haese PC
Semin Dial; 2006; 19(3):195-9. PubMed ID: 16689967
[TBL] [Abstract][Full Text] [Related]
15. Localization of lanthanum in bone of chronic renal failure rats after oral dosing with lanthanum carbonate.
Behets GJ; Verberckmoes SC; Oste L; Bervoets AR; Salomé M; Cox AG; Denton J; De Broe ME; D'Haese PC
Kidney Int; 2005 May; 67(5):1830-6. PubMed ID: 15840030
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic use of the phosphate binder lanthanum carbonate.
Barton Pai A; Conner TA; McQuade CR
Expert Opin Drug Metab Toxicol; 2009 Jan; 5(1):71-81. PubMed ID: 19236230
[TBL] [Abstract][Full Text] [Related]
17. Lanthanum carbonate, a phosphate binder, inhibits calcification of implanted aortic allografts in a rat model.
Kinoshita O; Yamauchi H; Motomura N; Ono M
Gen Thorac Cardiovasc Surg; 2019 May; 67(5):413-419. PubMed ID: 30374810
[TBL] [Abstract][Full Text] [Related]
18. Long-term treatment with lanthanum carbonate reduces mineral and bone abnormalities in rats with chronic renal failure.
Damment S; Secker R; Shen V; Lorenzo V; Rodriguez M
Nephrol Dial Transplant; 2011 Jun; 26(6):1803-12. PubMed ID: 21098011
[TBL] [Abstract][Full Text] [Related]
19. Vascular calcification is associated with cortical bone loss in chronic renal failure rats with and without ovariectomy: the calcification paradox.
De Schutter TM; Neven E; Persy VP; Behets GJ; Postnov AA; De Clerck NM; D'Haese PC
Am J Nephrol; 2011; 34(4):356-66. PubMed ID: 21876348
[TBL] [Abstract][Full Text] [Related]
20. Endochondral bone formation is involved in media calcification in rats and in men.
Neven E; Dauwe S; De Broe ME; D'Haese PC; Persy V
Kidney Int; 2007 Sep; 72(5):574-81. PubMed ID: 17538568
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
